KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Travere Therapeutics (TVTX) over the last 17 years, with Q3 2025 value amounting to $0.29.

  • Travere Therapeutics' EPS (Basic) rose 14142.86% to $0.29 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.03, marking a year-over-year increase of 7736.26%. This contributed to the annual value of -$0.01 for FY2024, which is 9977.12% up from last year.
  • As of Q3 2025, Travere Therapeutics' EPS (Basic) stood at $0.29, which was up 14142.86% from -$0.14 recorded in Q2 2025.
  • Travere Therapeutics' 5-year EPS (Basic) high stood at $1.97 for Q3 2023, and its period low was -$1.76 during Q1 2024.
  • Over the past 5 years, Travere Therapeutics' median EPS (Basic) value was -$0.7 (recorded in 2024), while the average stood at -$0.62.
  • In the last 5 years, Travere Therapeutics' EPS (Basic) crashed by 490000.0% in 2021 and then soared by 25038.17% in 2023.
  • Quarter analysis of 5 years shows Travere Therapeutics' EPS (Basic) stood at -$1.48 in 2021, then soared by 120.94% to $0.31 in 2022, then tumbled by 106.83% to -$0.02 in 2023, then surged by 100.24% to $0.0 in 2024, then soared by 571844.24% to $0.29 in 2025.
  • Its EPS (Basic) was $0.29 in Q3 2025, compared to -$0.14 in Q2 2025 and -$0.47 in Q1 2025.